{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T00:30:11Z","timestamp":1759624211956,"version":"build-2065373602"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T00:00:00Z","timestamp":1631664000000},"content-version":"am","delay-in-days":318,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100014812","name":"Nordic Pharma Group","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014812","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejog.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.ejogrb.2020.09.004","type":"journal-article","created":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T11:23:01Z","timestamp":1599564181000},"page":"95-101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Efficacy of mifepristone \u2013 Prostaglandin analogue combination in medical termination of pregnancy up to and beyond 7 weeks of amenorrhea: The RYMMa study."],"prefix":"10.1016","volume":"254","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8171-1418","authenticated-orcid":false,"given":"Aubert","family":"Agostini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Zinovieva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura Miquel","family":"Quaranta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne","family":"Herman-Demars","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Frantz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Sicot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2018","series-title":"224 300 interruptions volontaires de grossesse en","author":"Vilain","key":"10.1016\/j.ejogrb.2020.09.004_bib0005"},{"year":"2010","series-title":"Interruption volontaire de grossesse par m\u00e9thode m\u00e9dicamenteuse","author":"HAS","key":"10.1016\/j.ejogrb.2020.09.004_bib0010"},{"issue":"11","key":"10.1016\/j.ejogrb.2020.09.004_bib0015","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1034\/j.1600-0412.2001.801118.x","article-title":"Early pregnancy termination with mifepristone and misoprostol in Norway","volume":"80","author":"Bj\u00f8rge","year":"2001","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"4","key":"10.1016\/j.ejogrb.2020.09.004_bib0020","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.gyobfe.2005.02.021","article-title":"The efficacy and acceptability of mifepristone medical abortion with home administration misoprostol provided by private providers linked with the hospital: a prospective study of 433 patients","volume":"33","author":"Faucher","year":"2005","journal-title":"Gynecologie, Gynecol Obstet Fertil Senol"},{"issue":"1","key":"10.1016\/j.ejogrb.2020.09.004_bib0025","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejogrb.2005.11.001","article-title":"Consistency of medical abortion efficacy from 5 through 14 weeks\u2019 gestation","volume":"129","author":"Garbin","year":"2006","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"9","key":"10.1016\/j.ejogrb.2020.09.004_bib0030","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1093\/oxfordjournals.humrep.a138287","article-title":"The effect of dose of mifepristone and gestation on the efficacy of medical abortion with mifepristone and misoprostol","volume":"8","author":"McKinley","year":"1993","journal-title":"Hum Reprod"},{"issue":"5","key":"10.1016\/j.ejogrb.2020.09.004_bib0035","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1034\/j.1600-0412.2001.d01-462.x","article-title":"Medical abortion at 57 to 63 days\u2019 gestation with a lower dose of mifepristone and gemeprost: a randomized controlled trial","volume":"80","author":"World Health Organization Task Force On Post\u2010Ovulatory Methods Of Fertility Regulation","year":"2001","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"18","key":"10.1016\/j.ejogrb.2020.09.004_bib0040","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1056\/NEJM199804303381801","article-title":"Early pregnancy termination with mifepristone and misoprostol in the United States","volume":"338","author":"Spitz","year":"1998","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"10.1016\/j.ejogrb.2020.09.004_bib0045","first-page":"85","article-title":"Termination of early pregnancy (up to 63 days of amenorrhea) with mifepristone and increasing doses of misoprostol [corrected]","volume":"40","author":"Aubeny","year":"1995","journal-title":"Int J Fertil Menopausal Stud"},{"issue":"3","key":"10.1016\/j.ejogrb.2020.09.004_bib0050","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.contraception.2009.03.010","article-title":"Effectiveness of medical abortion with mifepristone and buccal misoprostol through 59 gestational days","volume":"80","author":"Fjerstad","year":"2009","journal-title":"Contraception"},{"key":"10.1016\/j.ejogrb.2020.09.004_bib0055","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ejogrb.2014.10.025","article-title":"Medical management of unwanted pregnancy in France: modalities and outcomes. The aMaYa study","volume":"184","author":"Nisand","year":"2015","journal-title":"Eur J Gynecol Reprod Biol"},{"issue":"4","key":"10.1016\/j.ejogrb.2020.09.004_bib0060","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.contraception.2015.01.005","article-title":"Efficacy and safety of medical abortion using mifepristone and buccal misoprostol through 63 days","volume":"91","author":"Gatter","year":"2015","journal-title":"Contraception"},{"issue":"1","key":"10.1016\/j.ejogrb.2020.09.004_bib0065","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/AOG.0000000000000897","article-title":"Mifepristone with buccal misoprostol for medical abortion: a systematic review","volume":"126","author":"Chen","year":"2015","journal-title":"Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.ejogrb.2020.09.004_bib0070","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.contraception.2004.11.010","article-title":"Comparison of gemeprost and vaginal misoprostol in first trimester mifepristone-induced abortion","volume":"72","author":"Svendsen","year":"2005","journal-title":"Contraception"},{"issue":"9","key":"10.1016\/j.ejogrb.2020.09.004_bib0075","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1034\/j.1600-0412.1999.780913.x","article-title":"Interruption of early pregnancy with mifepristone in combination with gemeprost","volume":"78","author":"Sandstr\u00f8m","year":"1999","journal-title":"Acta Obstet Gynecol Scand"},{"year":"2018","series-title":"WHO guidelines approved by the guidelines review committee","author":"WHO. Medical management of abortion","key":"10.1016\/j.ejogrb.2020.09.004_bib0080"},{"issue":"15","key":"10.1016\/j.ejogrb.2020.09.004_bib0085","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1056\/NEJM199504133321502","article-title":"Induction of abortion with mifepristone (RU 486) and oral or vaginal misoprostol","volume":"332","author":"El-Refaey","year":"1995","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ejogrb.2020.09.004_bib0090","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1097\/01.AOG.0000287291.19230.ba","article-title":"Toxic shock associated with Clostridium sordellii and Clostridium perfringens after medical and spontaneous abortion","volume":"110","author":"Cohen","year":"2007","journal-title":"Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.ejogrb.2020.09.004_bib0095","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1471-0528.1988.tb06840.x","article-title":"The effect of the antiprogestin RU 486 on uterine contractility and sensitivity to prostaglandin and oxytocin","volume":"95","author":"Swahn","year":"1988","journal-title":"BJOG: Int J Obstet Gynaecol"},{"issue":"3","key":"10.1016\/j.ejogrb.2020.09.004_bib0100","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1471-0528.2008.02034.x","article-title":"Two mifepristone doses and two intervals of misoprostol administration for termination of early pregnancy: a randomised factorial controlled equivalence trial","volume":"116","author":"Von Hertzen","year":"2009","journal-title":"BJOG: Int J Obstet Gynaecol"},{"issue":"2","key":"10.1016\/j.ejogrb.2020.09.004_bib0105","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.contraception.2015.08.010","article-title":"Predictors of uterine evacuation following early medical abortion with mifepristone and misoprostol","volume":"93","author":"Reeves","year":"2016","journal-title":"Contraception"},{"issue":"5","key":"10.1016\/j.ejogrb.2020.09.004_bib0110","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.ajog.2019.02.014","article-title":"Risk factors for surgical intervention of early medical abortion","volume":"220","author":"Meaidi","year":"2019","journal-title":"Am J Obstet Gynecol"}],"container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030121152030573X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030121152030573X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T05:49:00Z","timestamp":1759556940000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030121152030573X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":22,"alternative-id":["S030121152030573X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejogrb.2020.09.004","relation":{},"ISSN":["0301-2115"],"issn-type":[{"type":"print","value":"0301-2115"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of mifepristone \u2013 Prostaglandin analogue combination in medical termination of pregnancy up to and beyond 7 weeks of amenorrhea: The RYMMa study.","name":"articletitle","label":"Article Title"},{"value":"European Journal of Obstetrics & Gynecology and Reproductive Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejogrb.2020.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}